NCT05987332 2026-02-17IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal MelanomaIDEAYA BiosciencesPhase 2/3 Active not recruiting420 enrolled
NCT06624644 2025-09-10A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory MelanomaLinnaeus Therapeutics, Inc.Phase 2/3 Recruiting135 enrolled